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Abstract
Background: There is an ever-increasing need of monoclonal antibodies (mAbs) for biomedical applications and
fully human binders are particularly desirable due to their reduced immunogenicity in patients. We have applied a
strategy for the isolation of antigen-specific B cells using tetramerized proteins and single-cell sorting followed by
reconstruction of human mAbs by RT-PCR and expression cloning.
Results: This strategy, using human peripheral blood B cells, enabled the production of low affinity human mAbs
against major histocompatibility complex molecules loaded with peptides (pMHC). We then implemented this
technology using human immunoglobulin transgenic rats, which after immunization with an antigen of interest
express high affinity-matured antibodies with human idiotypes. Using rapid immunization, followed by tetramer-
based B-cell sorting and expression cloning, we generated several fully humanized mAbs with strong affinities,
which could discriminate between highly homologous proteins (eg. different pMHC complexes).
Conclusions: Therefore, we describe a versatile and more effective approach as compared to hybridoma generation
or phage or yeast display technologies for the generation of highly specific and discriminative fully human mAbs that
could be useful both for basic research and immunotherapeutic purposes.
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Background
Clinical use of monoclonal antibodies (mAbs) to treat
autoimmune diseases, transplantation and cancer is hav-
ing a tremendous medical impact [1]. More than 40
mAbs have been approved for clinical use in the United
States and Europe and a large number are currently in
development [2, 3]. Initially, mAbs were produced by
the immunization of laboratory animals, principally mice
and rats. Human recipient immune response against
murine mAbs is an important obstacle to their use due
to their rapid clearance [4, 5]. To solve this problem,
several strategies have been developed including the
modification of antibody protein sequences to decrease
immunogenicity, such as generation of chimeric mouse-
human or humanized antibodies, However, these strat-
egies increase the cost of production and often decrease
their affinity [6]. One solution is to generate human
mAbs and several strategies are available. One of them is
to use human B or plasma cells [7, 8], however this tech-
nique is restricted to antigens, such as infectious agents
following natural infection, and excludes many import-
ant targets that are either normal constituents of the
organisms and for which there is immune tolerance or
antigens that are harmful if administered, such as toxins.
Another technique is the use of phage or yeast display
but this generates antibodies with weak affinities, and
strategies to increase affinity are costly, time consuming
and not always successful. A more recent and effective
technique is the use of transgenic animals for human
immunoglobulin genes and in which their endogenous
immunoglobulin genes are deleted [9]. These immuno-
globulin humanized animals can then be immunized
with human proteins since their T and B cells will not be
tolerant towards these antigens and human antibodies
are produced through normal immune responses. The
majority of the human mAbs approved for therapy in
recent years have been generated in human immuno-
globulin transgenic mice [10] but other immunoglobulin
humanized transgenic animals, including rats [11–13]
and cattle [14] have been described. Overall, current
efforts have focused on the use of human mAbs that
have reduced immunogenicity after injection in humans
compared to chimeric or murine antibodies.
Recently developed human immunoglobulin transgenic
animals, such as the rats used in this study [11–13], do not
express rat immunoglobulins following genome editing
using zinc-finger nucleases and express chimeric im-
munoglobulin molecules with human antibody recog-
nizing domains and constant regions of rat origin.
This allows optimal interaction of cell membrane
immunoglobulin receptors with other components of
the B-cell receptor (BCR), with generation of anti-
bodies of optimal affinity and diversity displaying
extensive mutational changes that accumulate even in
rapid immunization schemes. At the same time, it is easy
to clone the human antibody sequences in expression
vectors containing human constant regions and therefore
obtaining fully human antibodies.
Until now, all human mAbs from mouse or rat human
immunoglobulin transgenic animals have been generated
using the classical hybridoma fusion of total B cells with
a myeloma cell line. It results in low frequency of B cell
fusing with the myeloma and is followed by intensive
cell culture and screening of many cell clones. The pro-
cedure is even more complicated when an antibody able
to discriminate between highly homologous proteins is
required. Thus, the technique of hybridoma generation
is time consuming as well as costly and there is need
for techniques that will increase efficiency of mAbs
generation.
In this study, we describe a procedure allowing selec-
tion and isolation of single antigen-specific B cells from
a heterogeneous population of B cells based on the use
of three color tetramerized antigens (Ags), previously
used for the isolation of peptide-major histocompatibility
(pMHC) specific T cells [15–17]. We demonstrate the
presence of naturally circulating pMHC-specific B lympho-
cytes in all human peripheral blood samples tested and
generated a human mAb against the HLA-A2/Pp65495
peptide complex derived from human CMV (hereafter
referred as to Pp65) but that displayed of low affinity. We
extended this strategy to human immunoglobulin trans-
genic rats and show that a rapid immunization method
[11, 12], followed by single antigen-specific B cell sorting
and expression cloning, allowed to obtain fully human
IgG high affinity mAbs against four different antigens
in ~6–8 weeks. The mAbs, obtained from rats immu-
nized with soluble HLA-A2/Pp65 complex showed
increased affinity compared to the one produced from
human peripheral blood lymphocytes (PBL) while con-
serving high peptide discriminative properties. Fur-
thermore, from two animals immunized with human
CD22, it was possible to generate at least 27 human
mAbs. Thus, the technique of antigen-specific B cell
sorting from immunoglobulin humanized rats allowed
efficient generation of human mAbs with high affinity
and discriminative capacity, likely against any desired
antigen. This tetramer-based antigen-specific B cell
sorting technique is a faster and more versatile alter-
native to the use of hybridoma fusion and could also




Cytapheresis samples were obtained from donors sero-
negative for HCMV, HCV, and HIV and presumably not
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at risk for infection and with no melanoma (Etablissement
Français du sang, EFS, Nantes).
Animals and immunisation
Human immunoglobulin transgenic rats were rendered
deficient for rat heavy, lambda and kappa chain expres-
sion using zinc-finger nuclease technology [11, 13] and
were made transgenic for human VH, DH and JH gene
segments linked to the rat heavy chain region as well as
fully human light kappa and lambda chains. These rats
expressed a diversified repertoire of antibodies with full
human idiotypes [11, 12]. Experimental protocols were
approved by the French regional ethical committee for
animal experimentation. Following a method previously
described that yielded high affinity antibodies [18], human
immunoglobulin transgenic rats were immunized at day 0
at each side of the tail base (intra muscular injection) with
100 μg of protein in Complete Freund Adjuvant (CFA)
and at day 16 with 100 μg of protein in PBS, then lymph
nodes and spleens were harvested at day 21.
Proteins and pMHC multimers
The following proteins were biotinylated with a DSB-X™
Biotin Protein Labeling Kit (ThermoFisher Scientific): β-
Galactosidase (Roche), CD22-Fc (BioTechne), CD22 (ProSci
Inc) and Ovalbumin (Roche). The HLA-A*0201–restricted
peptides Pp65495 (human CMV [HCMV], NLVPMVATV),
MelA27 (melanoma Ag, ELAGIGILTV), NS31073 (hepatitis
C virus [HCV], CINGVCWTV), GagP1777 (human Im-
munodeficiency Virus [HIV], SLYNTVAT) were purchased
from GL Biochem (Shanghaï, China). Soluble pMHC
monomers were synthesized as previously described
[19] HLA-A*0201 H chains used in this study carried
a mutation in the α3 domain (A245V), that reduces CD8
binding to MHC class I. Biotinylated proteins and pMHC
monomers were tetramerized with either Phycoerythrin
(PE)- or allophycocyanin (APC)-labeled premium grade
streptavidins (Molecular Probes, Thermo Fischer Scien-
tific, ref S21388 and S32362 respectively) or with Brilliant
Violet 421 (BV421)-labeled streptavidin (BioLegend,
ref 405225) at a molar ratio of 4:1.
Tetramer-based enrichment protocol and cell sorting
Sorting of human specific B cells
Human Peripheral Blood Mononuclear Cells (PBMCs)
were obtained by Ficoll density gradient centrifugation
(EurobioAbCys) and split for tetramer staining into tubes
containing 200x106 cells. Cells were incubated with
200 μL PE-, APC and BV421-conjugated tetramers di-
luted to 10 μg/mL in PBS plus 2% FBS for 30 min at
room temperature and then washed with 15 ml ice-cold
sorting buffer (PBS plus 0.5% BSA plus 0.2% EDTA).
The tetramer-stained cells were then enriched using
anti-PE and APC Ab-coated immunomagnetic beads
[20]. The resulting enriched fractions were stained with
anti-human CD3-BV510 (BD Biosciences) and anti-
CD19-PerCpCy5.5 (BD Biosciences) mAbs. Stained
samples were then collected on an ARIA Cell Sorter
Cytometer (BD Biosciences) and single CD19+ CD3−
PE+ APC+ BV421− tetramer cells were collected in
individual PCR tubes containing 10 μL of 1X PBS,
10 mM DTT (Thermo Fischer Scientific) and 10 units
of RNAse Out (Thermo Fischer Scientific) per well.
Single cells were frozen at -80 °C immediately. The
total number of tetramer-positive B cells was divided
by the total number of B cells within the starting
PMBC sample to calculate the frequency of pMHC-
specific B cells. Counting beads (Dako) were used to
normalize results.
Sorting of rat specific B cells
Spleen and iliac lymph nodes were harvested from im-
munized or unimmunized human immunoglobulin
transgenic rats 21 days after immunization and cell sus-
pensions prepared. Red blood cells were removed by
standard erythrocyte lysis. Cells were then stained with
anti-rat IgG (IgG1- and IgG2b-FITC, BD Biosciences)
and anti-TCR (R7.3-PerCp, BD Biosciences) mAbs for
30 min at 4 °C. Stained cells were then collected on an
ARIA Cell Sorter Cytometer and single IgG+ R7.3− PE+
APC+ and BV421− multimer cells were collected in indi-
vidual PCR tubes as for human specific B cells.
Single cell RT-PCR, cloning and IgG1 expression from
single B cells
Protocol for human B cells
The protocol was adapted from Tiller et al. [21] and Osborn
et al. [11]. Antigen specific human B cells in the original
PCR tubes were lysed by freezing at −80 °C, followed by
heating to 65 °C for 2 min. After cooling to 4 °C, total RNA
from the lysed single cell was reverse transcribed in a final
volume of 20 μL of 1X Superscript Buffer (Thermo Fischer
Scientific) containing 0.5 mM dNTP (Thermo Fisher Scien-
tific), 12.5 μg/mL oligod(T) primers (BioLabs), 2.5 μM
random hexamers (Thermo Fischer Scientific), 20 units of
RNAse Out (Thermo Fischer Scientific) and 200 units of
Superscript Reverse Transcriptase (Thermo Fischer Scien-
tific) for 1 h at 50 °C, after an initial step of 5 min at 25 °C
allowing random hexamers hybridation. The reaction was
stopped by incubation for 3 min at 95 °C. Variable region of
the rearranged heavy chain (HC) locus, lambda (LCλ) or
kappa (LCκ) light chain loci were next amplified separately
from each single cell cDNA by two round of nested PCRs.
For each variable segment, the first round of PCR was
performed on 3 μL of cDNA at 94 °C for 4 min, 94 °C for
30s, 58 °C for 30s for HC and LCκ (60 °C for LCλ,) and 55 s
at 72 °C for 40 cycles followed by a final elongation step at
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72 °C for 7 min in 1X GoTaq Buffer (Promega) containing
1.5 mM MgCl2 (Promega), 0.25 mM dNTPs (Thermo
Fischer Scientific), 2.5 units of GoTaq DNA Polymerase
(Promega), and 100nM of primers (see Additional file 1 for
primer sequences) in a 40-μL reaction volume. Four μL of
the first amplification products were further amplified by a
second round of PCR with inner- sense and anti-sense
primers complementary to the 5′ and 3′ ends of the VDJ
for heavy chain or VJ for light chain segments respectively
and containing at each extremity specific restriction en-
zymes sites for cloning into expression vectors. The second
round of PCR consisted of a denaturation step at 94 °C for
4 min and then 40 amplification cycles (30s at 94 °C, 30s at
58 °C for HC and LCκ/60 °C for LCλ, and 45 s at 72 °C) and
a final step at 72 °C for 7 min with 1X GoTaq Buffer
(Life Technologies), 1.5 mM MgCl2 (Life Technologies),
0.25 mM dNTPs (Life Technologies), 2.5 units of GoTaq
DNA Polymerase (Life Technologies), and 100nM of
primers (see Additional file 1 for primers sequences)
in a 40-μL reaction volume. PCR products from each
single cell were detected on a 1.5% agarose GelRed gel
(Sigma Aldrich).
PCR products from each well were purified by filtra-
tion through a NucleoFast 96 PCR plate (Macherey
Nagel, ref 743100.10) digested with respective restriction
enzymes in a total volume of 40 μL (AgeI-HF and SalI-
HF for HC, AgeI-HF and BsiWI for LCκ, AgeI-HF and
XhoI for LCλ). Inserts were respectively cloned into hu-
man Igγ1, Igκ or Igλ expression vectors (NCBI Genbank
accession numbers: FJ475055 IgG-AbVec, FJ475056 Igκ-
AbVec and FJ517647 Igλ-AbVec) containing multiple
cloning site upstream of human Ig constant regions and
kindly provided by P.C. Wilson [7]. Ligation was per-
formed in a total volume of 20 μL with 1 unit of T4
DNA-Ligase (Thermo Fischer Scientific), 5 μL of
digested and purified PCR product and 100 ng of linear-
ized vector. Electrocompetent E. Coli TOP10 bacteria
were transformed with 1 μl of the ligation products.
Colonies were screened by PCRs using 5′Absense as
the forward primer and 3′HuIgG, 3′Cκ494 or 3′Cλ as
the reverse primer, respectively. The expected insert
band is approximately 400 bp in length. To ensure a
consensus variable gene sequence was identified, for
each plate, plasmid DNAs from four positive colonies
were isolated using Nucleospin Plasmid Purification
Kit (Macherey-Nagel) according to the manufacturer’s
recommendations and sequenced. Sequences were analyzed
by IMGT/V-quest (http://www.imgt.org/IMGT_vquest/
share/textes/) to identify germline V(D)J gene segments
with highest identity and somatic mutations.
Human embryonic kidney 293A cells were grown as
adherent monolayers in DMEM supplemented with 10%
FBS and seeded the day earlier in order to reach 70% cell
confluency on the day of the transfection. Transient
transfections were performed using jetPEI™ (PolyPlus
transfection) at a ratio of 1 μg DNA (either 0.5 μg HC
and 0.5 μg LC expression vector DNA) to 2 μL jetPEI™
transfection reagent in a total volume of 100 μL in NaCl.
The media was removed and the transfection mix added
directly to the 293A cells, and 10% FBS DMEM (Thermo
Fischer Scientific) was added 2 h later. Cells were washed
after 16 h and cultured for 5 days in DMEM supple-
mented with 1% Nutridoma-SP (Roche). Supernatants
were then harvested 5 days later and the secreted mAbs
were purified on ProteinA-coated columns and measured
by the Recombinant Protein Platform (François Bonamy
Society) for MHC or pMHC specific mAbs.
Protocol for rat B cells
Single rat B cells in each sorting well received 50 μL of
lysis/binding buffer (100 mM TrisHCl (pH 7.5), 0.5 M
LiCl, 10 mM EDTA, 1% LiDS, 5 mM DTT) and 40 μg of
Dynabeads-oligo(dT)25 (Life Technologies). After 3-5 min,
the beads were washed with 100 μL of Wash buffer A
(10 mM TrisHCl (pH7.5), 0.15 M LiCl, 1 mM EDTA, 0.1%
LiDS) followed by two 50 μL washes with Wash buffer B
(10 mM TrisHCl (pH7.5), 0.15 M LiCl, 1 mM EDTA). A
final wash using 1x First-strand buffer was carried out before
setting up a cDNA synthesis reaction using 50U of Super-
script III reverse transcriptase (Life Technologies) and 10U
of rRNasin RNase inhibitor (Promega) in a 10 μL reaction
volume. After incubation (50 °C, 45 min), the beads were
washed with 10 mM Tris-HCl (pH 8.5). A first round PCR
was set up in a 30 μL volume of GoTaq Green Master mix
(Promega) containing 50nM of each VH and Vκ outer
primer and 130nM of both CγCH2 and Cκ outer
primers (see Additional file 1 for primer sequences).
PCR was performed for 38 cycles with an annealing
temperature of 59 °C and an extension of 1 min. A
second round PCR of 32-36 cycles was carried out as
described above, using 1 μL of the first round as template
and either VH inner primers plus CγCH1 or Vκ inner
primers and Cκ inner (see Additional file 1 for primer
sequences). The PCR products were then sequenced.
Mutated sequences obtained by single RT-PCR were
synthesized and cloned in expression vector by GeneArt™
Services at Thermo Fisher Scientific.
Transfection was performed using 2.5 μg of total DNA
(1.25 μg heavy chain plasmids + 1.25 μg light chain plas-
mids). On the day of transfection 2.5 μg of plasmid
DNA were diluted in 250 μL of Opti-MEM I medium
(Thermo Fisher Scientific) and 10 μl of Lipofectamine
(Thermo Fisher Scientific) were diluted in 250 μl of
Opti-MEM I medium and incubated at RT for 5 min.
DNA was then added to the Lipofectamine mixture and in-
cubated at RT for 20 min. Then the DNA-Lipofectamine
complexes were added to each well. Cells were incubated
for 5 days, and the supernatants were collected.
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CD22 and β-Galactosidase ELISA
Wells of Maxisorp 96 well flat bottom (Nunc) plates were
coated (O/N, 4 °C) with 5 μg/mL of CD22 recombinant
protein (ProSci-Inc) or β −Galactosidase protein (Roche)
in 50 μl of PBS and were then blocked with 5% BSA in
PBS for 2 h at RT. Fifty μL of supernatant were loaded in
duplicates wells and incubated for 2 h at 37 °C, followed
by the addition of 50 μL of anti human IgG biotinylated
antibody (1 μg/mL, Jackson Immunoresearch) for an add-
itional 90 min at 37 °C. HRP-conjugated streptavidin
(Jackson Immunoresearch, 1:5000) was added (45 min at
37 °C) and the reaction was visualized by the addition of
50 μL chromogenic substrate (TMB, BD biosciences) for
20 min. The reaction was stopped with 50 μl H2SO4 and
absorbance at 450 nm was measured with reduction at
630 nm using an ELISA plate reader. Plates were washed
three times with washing buffer (PBS, pH 7.4, containing
0.5% (v/v) Tween 20) after each step.
pMHC ELISA
Different monomers were coated O/N at 4 °C in 100 μL
of reconstituted ELISA/ELISPOT coating buffer 1X
(Affymetrix) at a final concentration of 2 μg/mL in 96-
well ELISA plates (Maxisorp, Nunc). Wells were blocked
with 10% FBS DMEM medium (Thermo Fischer Scien-
tific) for 2 h at 37 °C. MAbs generated from human PBMC
were not purified prior to testing by ELISA and therefore
50 μL of supernatants of transfected 293A cells were added
2 h at RT. MAbs generated from human immunoglobulin
transgenic rats immunized with HLA-A2/Pp65 were previ-
ously purified and added at 0.5 or 5 μg/mL in 50 μL of PBS
for 2 h at RT. An anti-human IgG-HRPAb (BD Biosciences)
was used for detection at 1 μg/mL and incubated for 1 h at
RT. The reaction was visualized by the addition of 50 μL
chromogenic substrate (TMB, BD biosciences) for 20 min.
OD were read at 450 nm.
Surface plasmon resonance
Surface Plasmon Resonance (SPR) experiments were
performed at 25 °C on a Biacore 3000 apparatus (GE
Healthcare Life Sciences, Uppsala, Sweden) on CM5
sensorchips (GE Healthcare). Capture mAbs were immo-
bilized at 10 μg/mL by amine coupling using a mixture of
N-hydroxysuccinimide and N-ethyl-N′-dimethylamino-
propyl carbodiimide, according to the manufacturer’s
instructions (GE Healthcare), after a 20-fold dilution in
sodium acetate buffer (10 mM, pH 5). Then, ethanolamine
(1 M, pH 8.5, GE Healthcare) was injected to deactivate
the sensor chip surface. Purified HLA-A*02:01 containing
the Pp65495 peptide were injected at various dilutions over
the capture antibodies 180 s at 40 μL/min. A flow cell left
blank was used for referencing of the sensorgrams.
Anti–HLA antibody testing (Luminex)
The specificity analysis of mAb 5.6 was performed using
Single Antigen Flow Bead assays according to the manu-
facturer’s protocol (LabScreen single-antigen LS1A04,
One Lambda, Inc., Canoga Park, CA), exploring 97 class I
alleles. The fluorescence of each bead was detected by a
Luminex 100 analyser (Luminex, Austin, TX), and re-
corded as the mean fluorescence intensity (MFI). The
positivity threshold for the bead MFI was set at 1000 after
removal of the background as previously reported [22].
Clinical relevance of pre-transplant donor-specific HLA
antibodies was detected by single-antigen flow-beads.
Staining experiments on HLA-A2+ cells
On T2 cells
One million Tap-deficient HLA-A2+ T2 cells were loaded
for 4 h at 37 °C with specific peptides at 50 μg/mL in
1 mL of 2% FBS RPMI medium (Thermo Fischer Scien-
tific). Cells were then washed with 10 mL PBS, harvested
and 1 × 105 cells were stained with purified test mAbs at
1 μg/mL in 200 μL of PBS 2%FBS for 30 min at 4 °C.
A secondary goat anti-human IgG-PE Ab (Abcam, ref
Ab98596) was added at 1 μg/mL in 50 μL for 30 min
at 4 °C. Unloaded T2 or T2 loaded with irrelevant
peptides were stained under the same conditions with
the same mAbs as controls. Cells were analyzed on a
BD FACS Canto II cytometer.
On CMV-infected MR5-cells
HLA-A2+ MRC-5 cells (RD-Biotech, Besançon, France)
were infected at a MOI = 0.1 with human cytomegalo-
virus (CMV) (Toledo strain) or left uninfected (control).
Cells were stained 72 h post-infection with test purified
mAb 1.5 at 2 or 10 μg/mL, 30 min at 4 °C in PBS, 0.1%
BSA. A secondary PE-conjugated Ab directed against
human IgGs (Abcam, ref Ab98596) was added at 1 μg/mL
in 50 μL for 30 min at 4 °C. After washing, cells were
resuspended in 300 μL PBS and analyzed on a LSR II
flow cytometer (BD Biosciences).
Blocking experiments on T cell lines
We previously generated, in the lab CRCNA UMR S892,
CD8+ T cell lines or clones specific to the A2/Pp65
cMelA specific/MelA specific CD8+ T cell lines [16]. 1 ×
105 T2 cells were loaded O/N at 37 °C in 200 μL of
10%FBS RPMI medium in 96-well round bottom plates
with Pp65 (10 pg/mL or 1 ng/mL) or MelA (1 μg/mL)
peptides. After washing of target cells, 1 × 105 T cells
were incubated with T2 cells in the presence of 10, 50 or
100 μg/mL of isotype control mAb, purified mAbs to be
tested or positive control mAbs (anti-HLA-A2 (clone
BB7.2), anti-Pan ClassI (clone G46-2.6); BD Biosciences)
and in the presence of anti-CD107a/b-FITC mAbs (BD
Biosciences), monensin (100nM) and brefeldinA (10 μg/mL)
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for 4 h at 37 °C in a total volume of 100 μL. Cells were then
stained with anti-CD3-APC H7 (BD Biosciences), fixed
and permeabilized with 100 μL of Fix/Perm Buffer 1X
(Affymetrix) and stained with anti-IFNγ-PE (BD Biosci-
ences) in PermBuffer 1X (Affymetrix). Cells were analyzed
on a BD FACS Canto HTS.
Results
Detection of pMHC-specific human B cells from healthy
human donors
For the detection of human B cells specific for pMHC
tetramers, we adapted a tetramer-based sorting strategy
described to measure the frequency of naive CD8+ T cells
directed against various HLA-A*0201(HLA-A2)/peptide
complexes in human healthy individuals [15–17]. Quite
surprisingly, during these analyses, we observed a low but
sizable fraction of CD3−CD19+ cells brightly stained by
the various HLA-A2/peptide tetramers tested. These in-
cluded HLA-A2/Pp65495, MelA27 derived from melanoma
antigen (Ag) and GagP1777 derived from HIV, suggesting
that B cells expressing specific-BCR might exist in the per-
ipheral blood of healthy donors. The enumeration of these
pMHC tetramer+ B cells was assessed in a cohort of 20
healthy donors after gating on cells positive for CD19 and
negative for CD3, CD14, CD16 and 7AAD. Relevant tetra-
mers with two different flurochromes were used in order
to efficiently exclude non-Ag-specific B cell binders pre-
sumably recognizing flurochromes as shown in Fig. 1a.
Importantly, an irrelevant tetramer associated with a third
flurochrome was used to enable exclusion of B cells that
could not discriminate the targeted Ag (anti-β2 micro-
globulin or anti-HLA-A2 complexed or not with other
peptides or anti-biotin). Average frequencies of antigen
specific cells within B lymphocyte pools were in the range
of 5 × 10−6-1 × 10−5 irrespective of the peptide presented
in the binding groove of HLA-A2 (Fig. 1b) and the large
majority were IgM+IgG− (data not shown). Proper specifi-
city of tetramer+ B cells was then assessed through single
cell sorting of rare B cells targeting HLA-A2/Pp65 without
any previous expansion from one donor, followed by a re-
construction of the antibody expressed by RT-PCR clon-
ing. Using this strategy, we were able to successfully
produce one HLA-A2/Pp65 specific antibody starting
from 3 sorted single B cells for which Ab-reconstruction
was successfully performed (Fig. 2 and data not shown).
Although ELISA assays clearly demonstrated this mAb
discriminated Pp65 peptide presented by HLA-A2 from
other peptides (Fig. 3a), it was not able to recognize HLA-
A2+ target cells exogenously loaded with a relevant pep-
tide (data not shown). Furthermore, its binding affinity,
determined by surface plasmon resonance (SPR), was low
(7 × 10−6M) (Fig. 3b). We thus described a sensitive proto-
col allowing detection of even scarce Ag-specific B cells
and the generation of highly discriminative human mAbs
starting directly from human PBL. Nevertheless, the fact
that isolation was performed from non-immune healthy
donors and most tetramer+ B cells were IgM+IgG− likely
reduces chances to obtain good Ag-binders. We therefore
implemented our strategy to an immunoglobulin human-
ized rat previously described for the generation of human
mAbs by the hybridoma fusion technique [11].
Tetramer-based isolation of antigen-specific B cells from
human immunoglobulin transgenic rats
For the generation of human mAbs in transgenic rats,
we deliberately selected antigens of variable difficulty:
notably, mAbs that could discriminate between HLA al-
leles and different peptides loaded on the same allele,
such as HLA-A2 and HLA-A2 loaded with Pp65. In this
last case, a specific antibody has indeed to recognize
both the peptide and the MHC molecule and to discrim-
inate the peptide in the MHC binding groove. We also
selected two other antigens, human CD22 and bacterial
β-galactosidase (β-gal).
Rats were immunized with these purified reagents and
lymph nodes tested for the presence of Ag-specific B
cells. Oligomerization of Ags was performed using fluo-
rescently tagged streptavidins for pMHC complexes,
CD22 and β-gal proteins. All fluorescently labeled com-
plexes were used with a set of mAbs for identification of
IgG+ B cells.
Detection and isolation of Ag-specific B cells from
transgenic rats by cytometry was similar to the one used
for human samples shown in Fig. 1, except the use of an
anti-TCR (clone R7.3) antibody for T cell-exclusion and
anti-IgG1 and 2b antibodies for positive selection of
IgG-expressing B cells (locus γ2a was absent in the
transgenic construct [11]). These latter cells were more
abundant in immunized transgenic rats than in naive
ones (a 5-6 fold increase on average) (Fig. 4a). IgG1/2b+
B cells stained by relevant tetramers were detected after
immunization of rats with all the antigens tested while
these B cells were not detectable in non-immunized ani-
mals (Fig. 4b). Once again, the relevant antigens were,
labeled with two different fluorochromes and used in as-
sociation with an irrelevant antigen labeled with a third
fluorochrome enabling exclusion of non-antigen specific
B cells. This exclusion was performed using an irrelevant
tetramer of ovalbumin (OVA) protein for the detection
of β-gal and CD22 specific B cells, a HLA-B7/irrelevant
peptide complex for the detection of HLA-A2 specific B
cells and a mix of HLA-A2/irrelevant peptides com-
plexes for the detection of anti-HLA-A2/Pp65 specific B
cells. As expected, this last exclusion strategy was very
important as the desired discriminative property of the B
cells for the Ag increases. In particular, selection of B
cells able to discriminate the HLA-A2/Pp65 complex
specifically required this negative selection strategy
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(Fig. 4b, panel 4) as we observed that most B cells
stained by the HLA-A2/Pp65 complex were also able to
recognize peptide-loaded HLA-A2 complexes, most-
likely because they recognized β2-microglobulin or
HLA-A2 specific-epitopes. The tetramer-based strategy
thus allows a precise identification of Ag-specific B
cells from immunized animals and an initial screening
for B cells capable of discriminating between highly
a
b
Fig. 1 Detection of HLA-A2/Pp65 specific B cells from human PBMC. a Gating strategy for HLA-A2/Pp65 specific B cells. After immunomagnetic enrichment
with HLA-A2/Pp65 tetramers and staining with additional fluorescent mAbs, cells were analyzed by flow cytometry. Cells were gated first on viable singlet
lymphocytes, then on CD19+CD3− cells. B cells that stained with both HLA-A2/Pp65-PE and HLA-A2/Pp65-APC tetramers were gated. Cells were also stained
with HLA-A2/irrelevant peptides to exclude B cells that were not against HLA-A2/Pp65. b The frequency of HLA-A2/MelA (n = 36), HLA-A2/
Pp65 (n = 37), HLA-A2/GagP17 (n = 28) specific B cells was determined among total peripheral B cells in healthy donors
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homologous proteins before expression cloning and
production of specific mAbs as depicted in Fig. 2.
Binding properties of human mAbs from single B cells
Single IgG1/2b+ B cells were isolated for every Ag tested
and specific mAbs were obtained in every instance
(Table 1). The proper specificity of these mAbs was ana-
lyzed and results show exquisite specificity for their re-
spective ligands such as discrimination between the Fc
and CD22 moieties of the Fc-CD22 molecule used
for immunization and between pMHC in a peptide-
dependent manner (Fig. 5a). Affinity was measured
by SPR and all antibodies showed high binding affinities:
anti-β-gal mAb, KD = 1 × 10
−10 to 1 × 10−7M; anti-CD22,
KD = 1.6 × 10
−9M; anti-HLA-A2 mAb, KD = 1.27 × 10
−8M;
anti-HLA-A2/Pp65 = KD: 1.44 × 10
−7M and 5.94 × 10−8M
(Fig. 5b, Table 1). In the latter case, a 2 log fold increase in
affinity was observed between HLA-A2/Pp65 specific
mAbs generated from humanized rats versus human
B cells, highlighting the efficiency of the humanized
rat system.
Anti-HLA-A2 and anti-HLA-A2/pPp65 mAbs gener-
ated with transgenic rats were further examined in order
to evaluate their ability to discriminate specific ligands
from other highly related Ags (i.e. other pMHC com-
plexes) in more physiological contexts. The anti-HLA-
A2 mAb (clone 5.6) was first tested in a Luminex assay
against microbeads loaded with class I antigens. As
shown in Fig. 5c, this antibody recognized HLA-A*0201
and all the HLA-A group but was poorly or not react-
ive against most HLA-B or -C antigens, demonstrating
its ability to discriminate between MHC-groups but
not between HLA-A alleles. Although B cells after
immunization of human immunoglobulin transgenic
rats were initially selected for their ability to bind
HLA-A*0201 tetramers, this global anti-HLA-A speci-
ficity was at least in part expected as the initial exclu-
sion strategy of Ag-specific B cells was performed
using HLA-B7 complexes and not other HLA-A al-
leles. The anti-HLA-A2/Pp65 mAbs (clones 1.5 and
2.7) were not able to recognize any MHC class I
loaded beads in Luminex assays (data not shown).
Both anti-HLA-A and anti-HLA-A2/Pp65 mAbs were
then tested for their ability to (i) recognize target cells
expressing or not HLA-A2 loaded with relevant or ir-
relevant peptides (ii) inhibit specific-T cell activation in a
MHC or pMHC restricted manner and (iii) specifically
bind HLA-A or HLA-A2/Pp65 complexes generated
under naturally occurring physiological Ag-processing
(i.e. viral infection) (Fig. 6). While the anti HLA-A mAb
(clone 5.6) was able to recognize HLA-A2+ target cells
and block activation of HLA-A2 reactive T cell clone or
lines, in a MHC group-A dependent manner but irre-
spective of the loaded-peptide, the anti-HLA-A2/Pp65
mAbs (clones 1.5 and 2.7) were dependent on both the
peptide and the expression of HLA-A2 (Fig. 6a and b).
Human embryonic fibroblasts, expressing or not HLA-
A2, were next infected with the HCMV laboratory strain
Toledo at a MOI of 0.1. Seventy-two hours later, a
strong decrease in the expression of HLA-A on the
surface of the virus-infected cells was observed, in
agreement with the previously documented HCMV-
induced downregulation of MHC expression (Fig. 6c
bottom) [23]. Although the overall MHC-expression
Fig. 2 Overall strategy of reconstruction of recombinant human mAbs. A tetramer-based sorting strategy allows detection of B cells of interest.
Tetramer+ B cells were single cell sorted. Light and heavy chain variable encoding segments were amplified using RT-PCR. Antibody genes PCR
products were sequenced directly and cloned into separate eukaryotic expression vectors in frame with constant light and heavy regions genes.
Expression of the corresponding fully human mAbs by transiently-transfected HEK 293 cells was purified from the culture supernatant
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on infected cells was strongly affected, the anti-HLA-
A2/Pp65 mAb 1.5 was able to stain infected cells in
an HLA-A2 dependent manner, demonstrating its ability
to recognize a naturally generated viral peptide/MHC
ligand (Fig. 6c upper).
Our strategy shows that human immunoglobulin
transgenic rats can efficiently generate high affinity
human mAbs against all tested antigens, and these are
capable of discriminating between highly homologous
proteins without cell culture techniques.
Overall yield recovery of human mAbs from transgenic
rats
The initial screening of selected B cells was performed
for various antigens but on a limited number of cells.
From a total of 75 single isolated B cells (n = 14 for β-gal,
30 for CD22-Fc, 7 for HLA-A2, 24 for HLA-A2/Pp65),
couples of heavy and light chain segments for a single B
cell clone were amplified 50% of the time, irrespective
of the targeted Ag (Table 1). Sequence analysis of amp-
lified heavy chain encoding segments confirmed that all
purified B cells expressed IgG (Additional file 2: Table
S1). We also observed a variety of different VJ or VDJ
segments (Additional file 2: Table S1), in agreement with
the previously demonstrated ability of humanized rats to
produce diverse B cell responses [11]. Most analyzed se-
quences revealed the presence of somatic hypermutations,
indicating that these cells had undergone affinity matur-
ation (Additional file 2: Table S1). Efficient production of
corresponding recombinant mAbs was obtained for all
a
b
Fig. 3 Characterization of a HLA-A2/Pp65 specific mAb (PC1.02) isolated from human peripheral blood. a Specificity of mAbs by ELISA. Plates were
coated with relevant (HLA-A2/Pp65) or irrelevant HLA-A2 complexes containing HLA-A2-restricted peptides: MelA, NS3 (HCV-1) and GagP17 (HIV-1) at
2 μg/mL, the mAb PC1.02 was added and an anti-human IgG-HRP Ab was used for detection. OD were read at 450 nm. b Affinity determination of
the mAb PC1.02 using SPR by flowing various concentration of A2/Pp65 complexes over CM5 chip-bound mAb
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Fig. 4 (See legend on next page.)
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specificities with a global recovery yield of 42% (Table 1), but
with large variations depending on the Ag-“complexicity”.
As an example, 8 anti-β-gal mAbs were generated
from 8 couples of heavy and light chains segments
(recovery = 100%), while only 3 anti-HLA-A2/Pp65
mAbs were obtained from 9 couples (recovery = 33,3%),
underlining the difficulty for these mAbs to recognize
both the peptide and the MHC molecule.
Although we were able to obtain Ag-specific mAbs
in all cases (Table 1), a deeper analysis of the yield
recovery was performed from two rats immunized
against human CD22. Three weeks after immunization,
the lymph nodes were collected and among IgG1/2b+
B lymphocytes, 123 were specifically stained by CD22
tetramers. Single cell RT-PCR was performed on 72 of
these B cells resulting in amplification of both heavy
and light chains encoding segments in the same B cell
in 44 of them (total efficiency of 61%, Table 1). Se-
quence analysis confirmed the induction of a poly-
clonal secondary B-cell response in the immunized rat
and the presence of many somatic hypermutations
(Additional file 3: Table S2). These 44 mAbs were then
produced by expression cloning and transfection
followed by screening for their ability to recognize
CD22 by ELISA and cytometry (Fig. 7a and b). From
these 44 paired sequences, 27 specifically recognized
CD22 protein by ELISA analysis (Fig. 7a), reacting with
different intensities that were not correlated by levels
of IgG expression in each transfectant (data not
shown). Analysis by cytometry showed that 20 of the
44 mAbs reacted against CD22+ target cells and not
against CD22− target cells and these were among the
27 depicted by ELISA (Fig. 7b). The absence of CD22
detection by cytometry by some mAbs (7/27) is pos-
sibly explained by detection of epitopes presented by
denatured CD22 proteins used in the ELISA analysis,
not expressed in the natural cell membrane conform-
ation, or due to low antibody affinities. From these 27
mAbs, further analyses of 4 of them randomly chosen
showed for all a high affinity (>2.43 nM) and all recog-
nized human blood B cells. An additional file shows
this in details (see Additional file 4).
Discussion
Using multiparametric single cell sorting of highly
antigen-specific B cells from the blood of human donors
followed by expression cloning of immunoglobulin
genes, we generated human mAbs. These mAbs were
highly specific since they discriminated between different
pMHC complexes. Nevertheless, they were of TCR-like
affinity (between 1 and 10 × 10−6M). Indeed, most B cells
isolated from human blood and against a protein target
were naïve (IgM+ IgG−), in agreement with the fact that
human donors were not immunized against these par-
ticular Ag. Immunoglobulin humanized transgenic rats
produced highly diverse and near normal expression
levels of antibodies with human idiotypes [11, 12].
Using a classical long immunization protocol into the
footpad resulting mainly in antigen-specific B cells in
the spleen followed by the hybridoma technique, we
(See figure on previous page.)
Fig. 4 Detection and isolation of Ag-specific IgG1/2b+B cells from immunized human immunoglobulin transgenic rats. After immunomagnetic
enrichment with Ag tetramers and staining with fluorescent mAbs, cells were analyzed on flow cell sorter. a Dots plots show viable and singlets
lymphocytes stained with anti-IgG1/2b and anti-TCR (clone R7.3). MAbs from one unimmunized and one immunized human immunoglobulin
transgenic rats is shown. b Dots plots show B cells stained with relevant Ag tetramers on unimmunized (left) and immunized (right) human
immunoglobulin transgenic with β-Gal, CD22 and HLA-A2/Pp65 Ags. Cells were also stained with irrelevant Ag tetramers to exclude unspecific B
cells. Cells from human immunoglobulin transgenic rats immunized with β-Gal and CD22 were stained with ovalbumin tetramers to exclude
streptavidin specific B cells. Cells from human immunoglobulin transgenic rats immunized with HLA-A2/Pp65 were stained with HLA-B7/irrelevant
peptide tetramers to exclude streptavidin and pan class I MHC-specific B cells, or with HLA-A2/irrelevant peptide tetramers to exclude streptavidin
and HLA-A2 specific B cells
Table 1 Analysis of isolated antigen-specific B cells
















β-galactosidase 14 12 8 (57%) Yes 8 1 × 10−10 to 1 × 10−7M
Fc-CD22 30 6 6 (20%) Yes 1 anti-CD22; 2 anti-Fc 1,6 × 10−9M
HLA-A 7 6 6 (86%) Yes 1 1,27 × 10−8M
HLA-A2/Pp65 24 11 9 (38%) Yes 3 6.10−8 to 1,4.10−7M
CD22 72 49 44 (61%) Yes 27 Not determined
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previously showed the generation of human mAbs
against several proteins [11]. Although well estab-
lished, this immunization protocol takes more than
6 weeks and requires administration of 400 μg of
antigen [11]. Furthermore, the hybridoma technique is
costly and time consuming. Thus, we developed a
rapid and efficient immunization protocol allowing
rapid production of antigen-specific B cells in the
draining lymph nodes followed by the same single cell
multiparametric sorting of antigen-specific B cells and
expression cloning of immunoglobulin genes used
from human PBMCs. In three weeks using 200 μg of
antigen, it has been described that high affinity anti-
bodies are generated [18] and we show here that spe-
cific B cells could be isolated from medial iliac lymph
nodes. Single cell RT-PCR and sequencing of the im-
munoglobulin genes of these B cells showed a high
proportion of mutated IgG sequences with high affin-
ity, regardless of antigen provenance (human or not)
and regardless of the size of proteins. This rapid affinity
maturation has already been described [24].
The gating strategy to isolate Ag-specific B cells re-
quired three colors for antigen labeling (two relevant
and one irrelevant or related Ags). Similar techniques
using only two colored Ags allowed isolation of antigen-
specific B cells from immunized wild type mice (one color
for the specific antigen and another one for a nonspecific
protein) [25] or from HIV-specific blood B cells from
HIV+ patients (two color Ag specific labeling) [8] have
been described. Compared with the latters, the 3 color
gating strategy improved the antigen-specificity of the
sorted B cells since the 2 antigen-specific colors allow
exclusion of fluorochrome-specific B cells, while the
third irrelevant/related Ag allows to gate-out streptavidin
and biotin-specific B cells and could offer the possibility
to identify B cells able to discriminate between highly
related-Ags. This latter point is best exemplified by our
ability to generate HLA-A2/Pp65-specific human mAbs
from human PBL or humanized rats. In that particular
case, the use of an HLA-A2/irrelevant peptide complex is
mandatory to eliminate or reduce, biotin, streptavidin,
β2-microglobulin, but also HLA-A2 specific B cells
a b
c
Fig. 5 Specificity and affinity of mAbs generated from human immunoglobulin transgenic rats single B cells. a Specificity ELISA of mAbs
generated from human immunoglobulin transgenic rats immunized with β-Gal (upper panel), CD22 (middle panel) and HLA-A2/Pp65 (lower panel). Upper
panel: a representative anti-β-Gal specific mAb (F2.2) among those generated, a control mAb that nonspecifically binds to different proteins (Ctrl mAb) and a
positive control human anti-β-Gal mAb previously generated by us [11]. Middle panel: 4D1 mAb did not recognize any epitope on CD22-Fc fusion-protein,
4C1 mAb recognized an epitope on the Fc domain of the fusion-protein, whereas 5E1mAb specifically recognized the CD22 protein. Lower panel: mAbs 1.5
and 2.7 recognized only the HLA-A2/Pp65 monomer, mAb 5.6 recognized all monomers containing the HLA-A2 molecule and anti-HLA-A2 mAb clone BB7.2
was added as a positive control. b Determination of the affinity of mAbs 5.6 and 1.5 generated from human immunoglobulin transgenic
rats immunized with HLA-A2/Pp65 using surface plasmon resonance by flowing various concentration of HLA-A2/Pp65 complexes over
CM5 chip-bound mAb. c Analysis of the specificity of mAb 5.6 in a Luminex single antigen bead assay. Results are shown in terms of
interval MFI. Positivity threshold was set at 1000
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a c
b
Fig. 6 (See legend on next page.)
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that do not discriminate the peptide in the HLA-A2
binding groove. The use of 3 colored Ags has recently
been performed to isolate anti-citrullinated-specific B
cells from rheumatoid arthritis patients [26] but has
not been yet exploited to isolate B cells able to dis-
criminate between related/homologous antigens and
to produce corresponding human mAbs from human
or animals. One anti-HLA-A2/Pp65 mAb tested rec-
ognized the epitope with high affinity (6x10−8M)
allowing detection in CMV infected cells and thus
could be a useful reagent for diagnostic or even thera-
peutic purposes. This antibody will be tested in the
future for its capacity to kill cells by ADCC or by using
its antigen-binding domain to generate a chimeric-antigen
receptor then expressed by cytotoxic T lymphocytes. It is
noteworthy that this HLA-A2/Pp65-specific mAb showed
a two log increase affinity compared to the one that we
obtain from human PBL and one log over an anti-
HLA-A2/Pp65 generated by phage display [23]. These
observations underlie the power of human immunoglobu-
lin transgenic animals system where immunization with
virtually any human or microbial protein could be easily
performed. Moreover, we readily obtained high affinity
mAbs (1x10−8 to 1x10−10M) against the other antigens
targeted in our study (human CD22, β-Galactosidase,
and HLA-A2).
Previous studies have questioned the suboptimal
performance of human immunoglobulin transgenic
animals, such in transgenic mice, both in terms of
the diversity and affinity of the antibodies generated
[10]. Indeed, an imperfect interaction between the
constant region of the human immunoglobulin,
expressed on the B cell membrane, and the mouse B-
cell receptor (BCR) signaling machinery, could de-
crease the efficacy and quality of antibody production
[27]. A successful strategy to overcome this has been
to generate transgenic animals carrying a heavy im-
munoglobulin transgene locus in which human im-
munoglobulin VH, DH, and JH segments have been
linked to mouse [28] or rat [11] heavy immunoglobu-
lin constant chain loci. In this situation, membrane
antibodies with a constant region from the transgenic
species interact optimally with other components of
the BCR. These transgenic rats also harbor an entirely
human immunoglobulin light chain transgene locus.
We demonstrate in the present study that B cells
from human immunoglobulin transgenic rats express
a normal diversity of antibodies with human idiotypes
of high affinity against various Ags. These can be eas-
ily converted to fully humanized Abs by cloning the
variable sequences in an expression vector containing
human constant heavy chain sequences [11].
The cell sorting strategy of positively selecting IgG+
specific B cells resulted in a high percentage of specific
mAbs. For example, following CD22 immunization,
61.4% of IgG+ cells were CD22 specific, with β-Gal
immunization, 100% of IgG+ cells were β-Gal specific
and with HLA-A2/Pp65 immunisation, 33.3% of IgG+
cells were HLA-A2/Pp65 specific. In comparison, 4 to
14% of total hybridomas are estimated to be Ag specific
using the hybridoma technique [29]. Twenty-seven anti-
CD22-specific mAbs were obtained using 58% of the
total number of antigen-specific B cells from 2 animals.
Assuming that all the antigen-specific B cells would have
been analyzed from a given animal, a recovery estimate
of 20 specific mAbs could be inferred per animal. Com-
pared to hybridoma generation, multiparametric cell
sorting of Ag specific B cells followed by single cell
RT-PCR analysis, sequencing and cloning in expres-
sion plasmids, considerably reduces the time required
to isolate specific mAbs by eliminating cell culture to
isolate and expand hybridomas. A drawback of our
technique is that it relies on the availability of puri-
fied antigen to be labelled with biotin and perform B
cell sorting. Importantly, the immunization step could
be replaced by DNA immunization or using cells ex-
pressing a given antigen.
Because plasma cells secrete high affinity antibodies,
it would be very desirable to isolate antigen specific
plasma cells. By using a reticulum endoplasmic marker
and fluorescent antigen staining, Kurosawa et al. dem-
onstrated the feasibility of isolating polyclonal plasma/
(See figure on previous page.)
Fig. 6 Use of mAbs generated from human immunoglobulin transgenic rats immunized with HLA-A2/Pp65 in functional experiments. a T2 cells
(HLA-A2+) were loaded for 4 h with different peptides at 50 μg/mL or not (unloaded T2 cells), then stained with purified anti-HLA-A or anti-HLA-
A2/Pp65 mAbs (clones 1.2, 1.5, 2.7 and 5.6) at 1 μg/mL. A secondary Ab anti-human IgG-PE was added at 1 μg/mL. Cells were analyzed on a BD
FACS Canto II cytometer. Specific anti-HLA-A2/Pp65 staining was observed with mAbs 2.7 and 1.5. b One A2/Pp65 specific T cell line, one A2/
Pp65 specific T cell clone and one A2/MelA specific T cell line were stimulated with T2 cells loaded O/N respectively with Pp65 or MelA peptides
in the presence of 10, 50 or 100 μg/mL of isotype control mAb, purified mAbs to be tested or positive control mAbs (anti-HLA-A2 (clone BB7.2),
anti-pan ClassI; BD Biosciences). The percent inhibition of T-cell activation is indicated in the figure (read-out: IFNγ production). Three independent
experiments were performed. c MRC-5 cells infected (MOI = 0,1) or not with CMV virus (Toledo strain) were stained 72 h post-infection with
purified mAb 1.5 at 2 or 10 μg/mL or not (MRC-5 cells without Ab). A secondary Ab anti-human IgG-PE was added at 1 μg/mL (upper panel).
Percentages of PE+ cells are indicated on dot plots in black, as well as the geometric mean of PE fluorescence in purple. Staining with an anti-
HLA-A2 mAb (BD Biosciences) was also performed on non-infected (grey line) or infected MR-5 cells (black line); dotted lines represents unstained
cells respectively (lower panel)
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plasmablast cells by FACS from humans and several
wild-type animals [30]. Subsequent expression of heavy
and light chains allowed them to produce mAbs. As
they demonstrated the capacity of plasma cells isola-
tion from rats, this technique is reasonably foreseeable
for transgenic rats. Other techniques have been applied
to generate mAbs, such as immortalization of human
B cells with Epstein Barr virus [31] but this strategy
has drawbacks linked to the use of human B cells de-
scribed above. Another technique used in immunized
a
b
Fig. 7 CD22 specificity analysis of antibodies by ELISA and flow cytometry. Supernatants from HEK 293 cells transfected with light and heavy
chain coding constructs from single anti-human CD22 B cells were analysed for reactivity against human CD22. a Human CD22 or β-Gal were
coated at a concentration of 5 μg/mL in 96-well plates. 50 μL of IgG expression supernatants collected 5 days after transfection were used pure
or diluted at 1:10 in PBS and used as the primary antibody. Biotin conjugated anti human IgG H + L antibody was used as the secondary antibody.
Streptavidin HRP was used for detection. OD450 read from blank control was deducted from all wells. Cell culture supernatants from human anti-
β-Gal H + L (clone 44A8, β-Gal Control) and CD22 H + L (clone 5E1, CD22 H + L Control) transfected cells were used as positive controls in β-Gal
and CD22 ELISA, respectively. Non-transfected cell culture supernatant was used as the negative control. b Representative flow cytometry analysis
of heavy and light chain co-transfected HEK cell culture supernatants. Supernatants from the indicated heavy + light chain positive transfections
in ELISA (the first 5 from left) or negative (the following ones) and were used as primary antibodies on Ramos CD22+ and NK92 CD22− cell lines.
Cell culture supernatants from human anti-CD22 H + L (clone 5E1, CD22 H + L) transfected cells and a commercial mouse mAb anti-human CD22
(Ms anti-hu CD22) were used as positive controls. Biotin conjugated anti human IgG H + L antibody was used as a secondary antibody and
streptavidin Alexa405 was used for cytometry detection. Histograms for transfected cell supernatant shown in black non-transfected cell
supernatant in filled grey. Control Ramos and NK92 cell lines were labelled with a commercial mouse anti human CD22 FITC (black line) or with
an isotype control (filled grey)
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animals is next generation sequencing coupled to bio-
informatic analysis to pair the more abundant heavy
and light chains [32] but this technique needs extensive
bioinformatic analysis as well cloning and expression of
sequences.
Conclusions
The use of human immunoglobulin transgenic rats, the
rapid immunization followed by an efficient single cell sort-
ing of antigen-specific IgG+ B cells, allowed production of
human IgG mAbs against all antigens tested, with high yield
affinity and discrimination, in a rapid manner. This tech-
nique could be easily implemented to other immunoglobu-
lin humanized species and adapted to virtually any desired
antigens which should open interesting perspectives both
for basic research and immunotherapeutic purposes.
Additional files
Additional file 1: Primer sequences. Primer sequences for Ag-specific Ig
amplification and for CD22-specific Ig (yield recovery of human mAbs).
(DOCX 122 kb)
Additional file 2: Table S1. Results of Ag-specific Ig genes sequencing.
(DOCX 113 kb)
Additional file 3: Table S2. Results of CD22-specific Ig genes sequencing.
(DOCX 141 kb)
Additional file 4: Analysis of anti-human CD22 human mAbs affinity
and specificity on human PBMCs. a) Affinity determination of anti-human
CD22 mAbs using SPR by flowing various concentration of CD22 anti-
body over CD22 chip-bound. b) Flow cytometry analysis of CD22 mAbs
on human PBMC. Human PBMC were labeled with anti human CD19
(APC) and purified CD22 mAbs (clone γ1λ1, γ3λ3-5, γ23κ5-2 or γ27λ26)
coupled with Alexa Fluor 568 fluorochrome or with a commercial mouse
mAb anti-human CD22 (Ms anti-human CD22). (PPT 666 kb)
Abbreviations
β-gal: β-galactosidase; Ag: Antigen; APC: Allophycocyanin; BCR: B-cell
receptor; BV: Brillant violet; CFA: Complete Freund Adjuvant; HC: Heavy chain;
LC: Light chain; mAbs: Monoclonal antibodies; OVA: Ovalbumine;
PBL: Peripheral Blood Lymphocytes; PBMC: Peripheral Blood Mononuclear
Cells; PE: Phycoerythrin; pMHC: Peptide-major histocompatibility complex;
SPR: Surface Plasmon Resonance; TCR: T-cell receptor
Acknowledgments
We thank the Cytometry Facility “CytoCell” (SFR Santé, Biogenouest, Nantes)
for expert technical assistance., We thank also all the staff of recombinant
protein production (P2R) and of IMPACT platforms (UMR-S892, SFR Santé,
Biogenouest, Nantes) for their technical support.
Funding
This work was financially supported by the IHU-Cesti project funded by the
« Investissements d’Avenir » French Government program, managed by the French
National Research Agency (ANR) (ANR-10-IBHU-005). The IHU-Cesti project is also
supported by Nantes Métropole and Région Pays de la Loire. This work was
performed in the context of the Labex IGO and TEFOR projects which are also part
of the « Investissements d’Avenir » French Government program managed by the
ANR (ANR-11-LABX-0016-01 and ANRI I-INSB-0014), respectively. The work was also
partially funded by Région Pays de la Loire through Biogenouest and by the IBiSA
program.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Authors’ contributions
LHO, LG, MCD, MO, MM, JV and FH performed the experiments. LHO, LG,
MCD, IA and XS wrote the manuscript. MB, RB, IA and XS supervised the
working program. All authors read and approved the final manuscript.
Competing interests
MO, MA, and RB are full employees of companies that commercialize human




Ethics approval and consent to participate
Blood samples were collected from healthy donors, with informed consents,
using the procedure (PLER NTS-2016-08) established between INSERM and
Etablissement Français du Sang (EFS). Experimental protocols were approved by
the French regional ethical committee (Comité d’Ethique en Expérimentation
Animale-Pays de la Loire, C2EA -06) for animal experimentation.
Author details
1INSERM Center for Research in Transplantation and Immunology (CRTI) U1064;
Université de Nantes; Centre Hospitalier Universitaire de Nantes Institut de
Transplantation Urologie Néphrologie (ITUN), Nantes F44000, France.
2Transgenesis Rat ImmunoPhenomic Platform Structure Fédérative de
Recherche François Bonamy Centre National de Recherche Scientifique
UMS3556, Nantes F44093, France. 3CRCNA UMR S892 INSERM 6299 CNRS
Université de Nantes; Université de Nantes Faculté des Sciences et Techniques,
Nantes F44093, France. 4CRCNA UMR S892 INSERM 6299 CNRS Université de
Nantes; Centre Hospitalier Universitaire de Nantes, Nantes F44093, France.
5Recombinant Antibody Technology Babraham Research Campus, Cambridge
CB22 3AT, UK. 6Centre Hospitalier Universitaire de Bordeaux Laboratoire
d’Immunologie et Immunogénétique Hôpital Pellegrin Bordeaux, Bordeaux
F33076, France. 7Université de Bordeaux UMR CNRS 5164 , Talence F33400,
France. 8Ligand Pharmaceuticals, San Diego, CA, USA.
Received: 12 July 2016 Accepted: 7 December 2016
References
1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal
antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;
12(5):615–22.
2. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and
inflammation. Nat Rev Immunol. 2010;10(5):301–16.
3. Pandey M, Mahadevan D. Monoclonal antibodies as therapeutics in human
malignancies. Future Oncol. 2014;10(4):609–36.
4. Golstein G, Schindler J, Tsai H, Cosimi AB, Russell PS, Norman D, Barry J,
Shield C. F., Cho SI, et al. A randomized clinical trial of OKT3 monoclonal
antibody for acute rejection of cadaveric renal transplants. N Engl J Med.
1985;313(6):337–42.
5. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic
monoclonal antibodies. Curr Opin Mol Ther. 2003;5(2):172–9.
6. Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications.
Trends Biotechnol. 2007;25(7):307–16.
7. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC.
Rapid generation of fully human monoclonal antibodies specific to a
vaccinating antigen. Nat Protoc. 2009;4(3):372–84.
8. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R,
Foulger A, Jaeger F, et al. Isolation of a human anti-HIV gp41 membrane
proximal region neutralizing antibody by antigen-specific single B cell
sorting. PLoS One. 2011;6(9):e23532.
9. Bruggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, Buelow R.
Human antibody production in transgenic animals. Arch Immunol Ther
Exp (Warsz). 2015;63(2):101–8.
10. Strohl WR. Antibody discovery: sourcing of monoclonal antibody variable
domains. Curr Drug Discov Technol. 2014;11(1):3–19.
11. Osborn MJ, Ma B, Avis S, Binnie A, Dilley J, Yang X, Lindquist K, Menoret S,
Iscache AL, Ouisse LH, et al. High-affinity IgG antibodies develop naturally in
Ig-knockout rats carrying germline human IgH/Igkappa/Iglambda loci
bearing the rat CH region. J Immunol. 2013;190(4):1481–90.
Ouisse et al. BMC Biotechnology  (2017) 17:3 Page 16 of 17
12. Ma B, Osborn MJ, Avis S, Ouisse LH, Menoret S, Anegon I, Buelow R,
Bruggemann M. Human antibody expression in transgenic rats: comparison
of chimeric IgH loci with human VH, D and JH but bearing different rat
C-gene regions. J Immunol Methods. 2013;400–401:78–86.
13. Menoret S, Iscache AL, Tesson L, Remy S, Usal C, Osborn MJ, Cost GJ,
Bruggemann M, Buelow R, Anegon I. Characterization of immunoglobulin
heavy chain knockout rats. Eur J Immunol. 2010;40(10):2932–41.
14. Matsushita H, Sano A, Wu H, Jiao JA, Kasinathan P, Sullivan EJ, Wang Z,
Kuroiwa Y. Triple immunoglobulin gene knockout transchromosomic cattle:
bovine lambda cluster deletion and its effect on fully human polyclonal
antibody production. PLoS One. 2014;9(3):e90383.
15. Hesnard L, Legoux F, Gautreau L, Moyon M, Baron O, Devilder MC,
Bonneville M, Saulquin X. Role of the MHC restriction during maturation
of antigen-specific human T cells in the thymus. Eur J Immunol. 2016;
46(3):560–9.
16. Legoux F, Debeaupuis E, Echasserieau K, De La Salle H, Saulquin X,
Bonneville M. Impact of TCR reactivity and HLA phenotype on naive CD8 T
cell frequency in humans. J Immunol. 2010;184(12):6731–8.
17. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM,
Jenkins MK. Naive CD4(+) T cell frequency varies for different epitopes
and predicts repertoire diversity and response magnitude. Immunity.
2007;27(2):203–13.
18. Kishiro Y, Kagawa M, Naito I, Sado Y. A novel method of preparing rat-
monoclonal antibody-producing hybridomas by using rat medial iliac
lymph node cells. Cell Struct Funct. 1995;20(2):151–6.
19. Bodinier M, Peyrat MA, Tournay C, Davodeau F, Romagne F, Bonneville M,
Lang F. Efficient detection and immunomagnetic sorting of specific T cells
using multimers of MHC class I and peptide with reduced CD8 binding.
Nat Med. 2000;6(6):707–10.
20. Moon JJ, Chu HH, Hataye J, Pagan AJ, Pepper M, McLachlan JB, Zell T,
Jenkins MK. Tracking epitope-specific T cells. Nat Protoc. 2009;4(4):565–81.
21. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H.
Efficient generation of monoclonal antibodies from single human B cells by
single cell RT-PCR and expression vector cloning. J Immunol Methods.
2008;329(1-2):112–24.
22. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical
relevance of pretransplant donor-specific HLA antibodies detected by
single-antigen flow-beads. Transplantation. 2009;87(11):1681–8.
23. Makler O, Oved K, Netzer N, Wolf D, Reiter Y. Direct visualization of
the dynamics of antigen presentation in human cells infected with
cytomegalovirus revealed by antibodies mimicking TCR specificity.
Eur J Immunol. 2010;40(6):1552–65.
24. Levy NS, Malipiero UV, Lebecque SG, Gearhart PJ. Early onset of somatic
mutation in immunoglobulin VH genes during the primary immune
response. J Exp Med. 1989;169(6):2007–19.
25. Hamilton JA, Li J, Wu Q, Yang P, Luo B, Li H, Bradley JE, Taylor JJ, Randall
TD, Mountz JD, et al. General approach for tetramer-based identification of
autoantigen-reactive B cells: characterization of La- and snRNP-reactive B
cells in autoimmune BXD2 mice. J Immunol. 2015;194(10):5022–34.
26. Kerkman PF, Fabre E, van der Voort EI, Zaldumbide A, Rombouts Y, Rispens
T, Wolbink G, Hoeben RC, Spits H, Baeten DL, et al. Identification and
characterisation of citrullinated antigen-specific B cells in peripheral blood
of patients with rheumatoid arthritis. Ann Rheum Dis. 2015;75(6):1170–6.
27. Pruzina S, Williams GT, Kaneva G, Davies SL, Martin-Lopez A, Bruggemann
M, Vieira SM, Jeffs SA, Sattentau QJ, Neuberger MS. Human monoclonal
antibodies to HIV-1 gp140 from mice bearing YAC-based human
immunoglobulin transloci. Protein Eng Des Sel. 2011;24(10):791–9.
28. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill
RS, Wilson S, Chowdhury P, et al. Identification of anti-alpha toxin
monoclonal antibodies that reduce the severity of Staphylococcus aureus
dermonecrosis and exhibit a correlation between affinity and potency. Clin
Vaccine Immunol. 2012;19(3):377–85.
29. Tsuji I, Sato S, Otake K, Watanabe T, Kamada H, Kurokawa T. Characterization
of a variety of neutralizing anti-heparin-binding epidermal growth factor-like
growth factor monoclonal antibodies by different immunization methods.
MAbs. 2012;4(6):732–9.
30. Kurosawa N, Yoshioka M, Fujimoto R, Yamagishi F, Isobe M. Rapid
production of antigen-specific monoclonal antibodies from a variety of
animals. BMC Biol. 2012;10:80.
31. Maskus DJ, Bethke S, Seidel M, Kapelski S, Addai-Mensah O, Boes A, Edgu G,
Spiegel H, Reimann A, Fischer R, et al. Isolation, production and
characterization of fully human monoclonal antibodies directed to
Plasmodium falciparum MSP10. Malar J. 2015;14:276.
32. Reddy ST, Ge X, Miklos AE, Hughes RA, Kang SH, Hoi KH, Chrysostomou C,
Hunicke-Smith SP, Iverson BL, Tucker PW, et al. Monoclonal antibodies
isolated without screening by analyzing the variable-gene repertoire of
plasma cells. Nat Biotechnol. 2010;28(9):965–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ouisse et al. BMC Biotechnology  (2017) 17:3 Page 17 of 17
